A commonly prescribed anti-osteoporosis drug works as well at preventing breast cancer in postmenopausal women as the sole drug currently prescribed for the task, a head-to-head trial shows.
Scientists designed the study to compare oral doses of the osteoporosis drug raloxifene (Evista) with tamoxifen (Nolvadex) taken for 5 years. Roughly half of the nearly 20,000 women received raloxifene; the others got tamoxifen. All the women were at high risk of breast cancer.
Researchers report that roughly the same number of women-167 and 163-developed breast cancer while taking raloxifene and tamoxifen, respectively.
However, 36 women getting tamoxifen developed uterine cancer, compared with only 23 taking raloxifene. Also, more women getting tamoxifen developed blood clots than did women taking raloxifene.